Skip to main content
. Author manuscript; available in PMC: 2014 Mar 1.
Published in final edited form as: Glia. 2012 Dec 22;61(3):394–408. doi: 10.1002/glia.22442

Figure 7. Analysis of GDH activity and differentiation of treated CTX8 cells.

Figure 7

Differentiation analysis of treated CTX8 cells. A-D: Merged images of representative DIV6 CTX8 cells with various treatments (A, Control; B, α-ketoglutarate; C, EGCG; D, trans-PDC). Scale bar represents 20 μM. E: Quantitation of cell density for each specific treatment to appreciate any changes in cell population. No significant changes in cell density with treatment occurred. F: Quantitation of changes in expression of Tuj1 and GFAP in DIV6 CTX8 cells with indicated treatment. Expression of “none” is defined as a cell with no visible expression of either tuj1 or GFAP. Compared to control conditions, there is a significant increase in the number of cells expressing neither Tuj1 or GFAP only with PDC treatment. Compared to control conditions, there is a significant decrease in the number of cells expressing Tuj1 with aKG and CNTF treatment. Compared to control conditions, there is a significant increase in the number of cells expressing GFAP with aKG and CNTF treatment, and a significant decrease in the number of cells expressing GFAP with PDC treatment. *p < 0.05 ** p < 0.01, ***p < 0.001. G: Quantitation of Normalized GDH activity using a GDH assay kit, as measured by absorbance at 450nm, from lysate of DIV6 CTX8 cells with indicated treatments. One way ANOVA followed by Dunnett’s showed that there was a significant decrease in GDH activity with trans-PDC treatment compared to control, * p <0.05, and a significant increase in GDH activity with CNTF treatment, * p <0.05.